普門科技(688389.SH):正在積極推進糖化血紅蛋白變異體庫大模型的開發工作
格隆匯5月29日丨普門科技(688389.SH)在投資者互動平臺表示,(1)公司正在積極推進糖化血紅蛋白變異體庫大模型的開發工作,研發成果情況請您關注公司後續披露的定期報告; (2)公司未來會堅持聚焦體外診斷和治療與康復兩大領域,同時保持對研發高投入的節奏,推動產品創新與技術升級,不斷提升公司產品的創新力和競爭力; (3)公司聚焦預防、急救、治療、康復和美好生活等人類健康幸福的需求,圍繞典型診療路徑的需求,拓展診療產品和解決方案。以業內國際知名醫學診療產品公司爲標杆,將公司建成可以有效駕馭多產品領域和多市場的平臺型企業,打造一流的醫學診療產品研發製造中心,持續推出對健康和生命具有顯著價值的產品,成爲體外診斷、臨牀醫療、皮膚醫美和消費者健康領域有核心競爭力和影響力的研發製造供應商。 (4)公司的在研項目可查閱《公司2024年年度報告》中的“在研項目情況”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.